Atransferrinemia

**Atranferrinomia** is a rare inherited disorder caused by a mutation in the gene that codes for a protein called transferrin. This occurs due to changes in the structure of blood molecules, which reduces their ability to bind and transport iron in the body.

**Clinical picture.**

Symptoms of atransferremia may vary depending on the severity of the disease. However, the disease typically appears early in life, often between 6 months and 2 years of age. Symptoms may include severe fatigue, loss of appetite and weight loss, as well as periodic bleeding (bruises) due to iron deficiency, which is caused by impaired iron binding and transport into the bloodstream, enlargement of the spleen, liver and heart.

Patients with atransferinemia may be at increased risk of developing cardiovascular disease, especially in children with inherited risk factors. The diagnosis is made according to clinical manifestations, as well as the results of blood tests revealing transferrin and iron deficiency.

Treatment of atransferonomia includes treating iron deficiency by prescribing iron supplements, such as ferrous gluconate or ferrocytark, and avoiding medications that can increase iron levels in the blood, such as aspirin, anticoagulants

Atransferrinymia is a rare hereditary disease caused by insufficiency or absence of synthesis of one of the main blood plasma proteins - transferrin (Tf). Monogenic disorders of transferrin metabolism lead to multiple and highly inherited tissue abnormalities, chronic anemia and an increase in blood viscosity or a change in its rheological properties, as well as the appearance of edema (myxodema), which is based on thrombosis and hypofibrinogenemia. In addition, transferrin has antioxidant properties and, together with superoxide dismutase, provides